Belite Bio, Inc

Rentabilité sur six mois: +0.8638%
Rendement en dividendes: 0%
Secteur: Healthcare

59.55 $

0 $ 0%
46.04 $
83.66 $

paper.min_max_per_year

Calendrier des promotions Belite Bio, Inc

Paramètres de base

IPO date
2022-04-29
ISIN
US07782B1044
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 13.77 1
P/E 0 0
Efficacité
Nom Signification Grade
ROA -29.29 0
ROE -30.6 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0172 10
Debt/Ratio 0.0035 10
Debt/Equity 0.0433 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 453.14 10
Rentabilité EPS, % 375.57 10

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 59.55 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 61.19 $ 0 $ 0 $ -2.68 % 0 % 0 %
common.calendar.number_days.30d 61 $ 0 $ 0 $ -2.38 % 0 % 0 %
common.calendar.number_days.90d 56.6 $ 58.23 $ 67.29 $ +5.21 % 0 % 0 %
common.calendar.number_days.180d 59.04 $ 53.8 $ 69.49 $ +0.8638 % 0 % 0 %
common.calendar.number_days.1y 48.87 $ 46.04 $ 83.66 $ +21.85 % 0 % 0 %
common.calendar.number_days.3y 25.1 $ 11.18 $ 83.66 $ +137.25 % 0 % 0 %
common.calendar.number_days.5y 8.87 $ 8.87 $ 83.66 $ +671.36 % 0 % 0 %
common.calendar.number_days.10y 8.87 $ 8.87 $ 83.66 $ +671.36 % 0 % 0 %
common.calendar.number_days.ytd 58.22 $ 53.04 $ 69.49 $ +2.28 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO N/A 1979 (46 années)
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director N/A 1985 (40 années)
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer N/A 1967 (58 années)
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board

Informations sur l'entreprise

Adresse: United States, San Diego. CA, 12750 High Bluff Drive - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://belitebio.com

À propos de l'entreprise Belite Bio, Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.